Compare IMXI & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMXI | DMAC |
|---|---|---|
| Founded | 1994 | 2000 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 460.6M | 428.6M |
| IPO Year | 2016 | 2018 |
| Metric | IMXI | DMAC |
|---|---|---|
| Price | $15.50 | $8.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $16.67 | $15.50 |
| AVG Volume (30 Days) | ★ 192.9K | 184.3K |
| Earning Date | 01-01-0001 | 02-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.82 | N/A |
| EPS | ★ 0.79 | N/A |
| Revenue | ★ $319,601,000.00 | $500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.95 | N/A |
| P/E Ratio | $19.63 | ★ N/A |
| Revenue Growth | ★ 16.68 | N/A |
| 52 Week Low | $8.58 | $3.22 |
| 52 Week High | $18.48 | $10.42 |
| Indicator | IMXI | DMAC |
|---|---|---|
| Relative Strength Index (RSI) | 50.88 | 53.95 |
| Support Level | $15.52 | $8.00 |
| Resistance Level | $15.63 | $9.04 |
| Average True Range (ATR) | 0.05 | 0.55 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 30.56 | 69.11 |
International Money Express Inc is a processor of money transfer services in the USA to the Latin America and the Caribbean (LAC) corridor. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.